Orthocell CEO Paul Anderson spoke with Jonathan Jackson at Proactive about the Company’s recent strategic placement of $3.5 million, adding prominent investors to the share register.
In the interview, he discusses how ample funding and a strong Board supports the Company as it advances its commercialisation plans for breakthrough nerve repair product, Remplir.
“This placement enables us now to freely drive these really exciting products – Remplir, in particular – into the US market. That takes us well through FDA approval, and really solidifies the position of the Company as we move into those US markets.”